Results of Geothermal Gradient Core Hole TCB-1, Tecuamburro Volcano Geothermal Site, Guatemala, Central America

Results of geological, volcanological, hydrogeochemical, and geophysical field studies conducted in 1988 and 1989 at the Tecuamburro volcano geothermal site in Guatemala indicated that there is a substantial shallow heat source beneath the area of youngest volcanism. To obtain information on subsurface temperatures and temperature gradients, stratigraphy, hydrothermal alteration, fracturing, and possible inflows of hydrothermal fluids, a geothermal gradient core hole (TCB-1) was drilled to 808 m low on the northern flank of the Tecuamburro volcano Complex, 300 km south of a 300-m-diameter phreatic crater, Laguna Ixpaco, dated at 2,910 years. Gases from acid-sulfate springs near Laguna Ixpaco consistently yield maximum estimated subsurface temperatures of 250--300{degrees}C. The temperature versus depth curve from TCB-1 does not show isothermal conditions and the calculated thermal gradients from 500--800 m is 230{degrees}C/km. Bottom hole temperature is 238{degrees}C. Calculated heat flow values are nearly 9 heat flow units (HFU). The integration of results from the TCB-1 gradient core hole with results from field studies provides strong evidence that the Tecuamburro area holds great promise for containing a commercial geothermal resource

sj-docx-1-dhj-10.1177_20552076221129729 - Supplemental material for Text messaging to increase patient engagement in a large health care for the homeless clinic: Results of a randomized pilot study

Supplemental material, sj-docx-1-dhj-10.1177_20552076221129729 for Text messaging to increase patient engagement in a large health care for the homeless clinic: Results of a randomized pilot study by Karyn Kershaw, Lisa Martelly, Cassidy Stevens, D. Keith McInnes, Allie Silverman, Thomas Byrne, Diana Aycinena, Lora L. Sabin, Lynn A. Garvin, Varsha G. Vimalananda and Robert Hass in Digital Health</p

Erratum:Rare EIF4A2 variants are associated with a neurodevelopmental disorder characterized by intellectual disability, hypotonia, and epilepsy (The American Journal of Human Genetics (2023) 110(1) (120–145), (S000292972200502X), (10.1016/j.ajhg.2022.11.011))

(The American Journal of Human Genetics 110, 120–145; January 5, 2023) In the originally published version of this article, the stock number of two fly lines, UAS-eIF4A and Nubbin-GAL4, are incorrectly mentioned. The correct stock number for UAS-eIF4A is FlyORF:F000979 and for Nubbin-GAL4 is BDSC #86108. This has now been fixed online. The authors regret this inadvertent error.</p

Identification of <i>N</i>‑(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)‑3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound <b>8</b> (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound <b>3</b>, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound <b>8</b> entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies